Different Angiogenic Potential in Low and High Grade Sporadic Clear Cell Renal Cell Carcinoma Is Not Related to Alterations in the von Hippel–Lindau Gene

Background: von Hippel–Lindau (VHL) inactivation is common in sporadic clear cell renal cell carcinomas (ccRCC). pVHL is part of the ubiquitin ligase complex that targets the alpha subunits of hypoxia-inducible transcription factor (HIF) for degradation under well-oxygenated conditions. In the absence of wild-type pVHL, as observed in VHL patients and most sporadic ccRCCs, constitutive upregulation of HIF results in transcriptional activation of angiogenesis-related genes, such as VEGF. Differences in angiogenic activity within the group of ccRCCs were reported and strong genotype-phenotype correlations were found in patients with VHL disease, raising a question about the importance of VHL inactivation status in angiogenic behaviour and tumour progression. Methods: To address this question, we investigated the influence of VHL mutation (direct sequencing)/hypermethylation (methylation-specific PCR) on angiogenesis/tumour parameters (immunohistochemistry) in 150 patients with sporadic ccRCC. Results: We found no significant association between VHL mutation or methylation and angiogenesis/tumour parameters. Conclusions: These data indicate that tumour progression and angiogenesis are not directly influenced by VHL alterations and that additional genetic/epigenetic events should be considered to explain the diverse angiogenic and proliferative behaviour during tumour progression.

[1]  S. Richard.  VHL (von Hippel-Lindau tumor suppressor) , 2011 .

[2]  P. A. van den Brandt,et al.  Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis , 2008, Clinical Cancer Research.

[3]  D. Chung,et al.  Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis , 2007, Clinical Cancer Research.

[4]  T. Roskams,et al.  High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT–PCR mRNA expression profile , 2007, British Journal of Cancer.

[5]  John P A Ioannidis,et al.  Is molecular profiling ready for use in clinical decision making? , 2007, The oncologist.

[6]  W. Kaelin.  The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma , 2007, Clinical Cancer Research.

[7]  K. Grankvist,et al.  Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray , 2006 .

[8]  Kentaro Takahashi,et al.  [Von Hippel-Lindau disease]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[9]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α , 2006 .

[10]  C. Taylor,et al.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.

[11]  Pei-yin Lin,et al.  Kidney cancer: identification of novel targets for therapy. , 2006, Kidney international.

[12]  E. van Marck,et al.  Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer , 2005, British Journal of Cancer.

[13]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[14]  J. Ioannidis.  Why Most Published Research Findings Are False , 2005, PLoS medicine.

[15]  F. Marshall.  Promoter hypermethylation profile of kidney cancer. , 2005, The Journal of urology.

[16]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[17]  P. A. van den Brandt,et al.  Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study , 2005, BMC Cancer.

[18]  K. Grankvist,et al.  The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Schalken,et al.  Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma , 2004, Oncogene.

[21]  R. Uzzo,et al.  Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. , 2003, Cancer research.

[22]  R. Klausner,et al.  Studying cancer families to identify kidney cancer genes. , 2003, Annual review of medicine.

[23]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[24]  E. Messing,et al.  Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.

[25]  R Alexandra Goldbohm,et al.  Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. , 2003, Cancer research.

[26]  J. Klco,et al.  Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. , 2003, Molecular cancer research : MCR.

[27]  E. Stanbridge,et al.  Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. , 2003, Cancer research.

[28]  A. Harris,et al.  Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. , 2002, Cancer research.

[29]  T. Shuin,et al.  Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters , 2002, Genes, chromosomes & cancer.

[30]  M. Esumi,et al.  Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. , 2002, The Journal of urology.

[31]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[32]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[33]  H. Moch,et al.  Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. , 2001, Cancer research.

[34]  H. Gröne,et al.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.

[35]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[36]  A. Harris,et al.  Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling , 2000, Oncogene.

[37]  L. Poellinger,et al.  Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.

[38]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[39]  P. Carmeliet,et al.  Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .

[40]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[41]  S. Richard,et al.  Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.

[42]  W. Linehan,et al.  Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. , 1996, The American journal of pathology.

[43]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Greenberg,et al.  Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. , 1995, Cancer research.

[46]  K. Kok,et al.  Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. , 1995, Genes, chromosomes & cancer.

[47]  O Yoshida,et al.  Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.

[48]  M. Ferguson-Smith,et al.  Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.

[49]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[51]  B. Teh,et al.  Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. , 2008, Cancer research.

[52]  D. Walsh.  Pathophysiological mechanisms of angiogenesis. , 2007, Advances in clinical chemistry.

[53]  M. Oya,et al.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. , 2007, Carcinogenesis.

[54]  J. Ioannidis.  Molecular Bias , 2005, European Journal of Epidemiology.

[55]  H. Brauch,et al.  Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p , 2004, World Journal of Urology.

[56]  J. Schalken,et al.  Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.

[57]  F. Waldman,et al.  Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. , 1996, Cancer research.

[58]  W. Linehan,et al.  Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.